ReviewIntegrative cancer therapies
Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy.
Review in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- The impact of pelvic radiotherapy on the gut microbiome and its role in radiation-induced diarrhoea: a systematic review.Radiation oncology (London, England) · 2021Pooled it
- Relating Gut Microbiome and Its Modulating Factors to Immunotherapy in Solid Tumors: A Systematic Review.Frontiers in oncology · 2021Pooled it
- Leveraging gut microbiota for enhanced immune checkpoint blockade in solid tumor therapy.Chinese medical journal · 2026Review
- Review
- Harnessing Machine Learning and Multiomics to Construct a Tumor-Specific T Cell Signature for Prognostic Assessment and Precision Medicine in Lung Adenocarcinoma.Annals of surgical oncology · 2026Article
- Mathematical Modeling and Association Analysis Decipher the Impact of the Gut Microbiome on Cancer Immunotherapy.Cancer research · 2025Article
- Impact of Chemotherapy Alone and in Combination with Immunotherapy on Oral Microbiota in Cancer Patients-A Pilot Study.Microorganisms · 2025Article
- Microbiota-mediated modulation of radiosensitivity: mechanisms and therapeutic prospects of oral and gut microbiota, metabolites, and probiotics.Frontiers in microbiology · 2025Review
- Recent advances in gut microbiota-based nanotherapies for cancer treatment.Frontiers in pharmacology · 2025Review
- An exploratory study of a multi-species probiotic formulation and markers of health in a real-world oncological cohort in the time of covid.Inflammopharmacology · 2024Article
- Gut microbiome affects the response to immunotherapy in non-small cell lung cancer.Thoracic cancer · 2024Article
- Efficacy and regulatory strategies of gut microbiota in immunotherapy: a narrative review.Translational cancer research · 2024Review
- Review
- Gut Microbiome Composition and Its Metabolites Are a Key Regulating Factor for Malignant Transformation, Metastasis and Antitumor Immunity.International journal of molecular sciences · 2023Review
- Advances in immunotyping of colorectal cancer.Frontiers in immunology · 2023Review
- Emerging role of human microbiome in cancer development and response to therapy: special focus on intestinal microflora.Journal of translational medicine · 2022Review
- The interplay between anticancer challenges and the microbial communities from the gut.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2022Review
- Novel directions of precision oncology: circulating microbial DNA emerging in cancer-microbiome areas.Precision clinical medicine · 2022Review
- Optimizing therapeutic outcomes of immune checkpoint blockade by a microbial tryptophan metabolite.Journal for immunotherapy of cancer · 2022Article
- Global research trends on the links between the gut microbiome and cancer: a visualization analysis.Journal of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the past decade, a growing set of immunotherapies including immune checkpoint blockade, chimeric antigen receptor T cells, and bispecific antibodies propelled the advancement of oncology therapeutics. Accumulating evidence demonstrates that immunotherapy could eliminate tumors better than traditional chemotherapy or radiotherapy with lower risk of adverse events in numerous cancer types. Unfortunately, a substantial proportion of patients eventually acquire resistance to immunotherapy. By analyzing the differences between immunotherapy-sensitive and immunotherapy-resistant populations, it was noticed that the composition of gut microbiota is closely related to treatment effect. Moreover, in xenograft models, interventional regulation of gut microbiota could effectively enhance efficacy and relieve resistance during immunotherapy. Thus, we believe that gut microbiota composition might be helpful to explain the heterogeneity of treatment effect, and manipulating gut microbiota could be a promising adjuvant treatment for cancer immunotherapy. In this mini review, we focus on the latest understanding of the cross-talk between gut microbiota and host immunity. Moreover, we highlight the role of gut microbiota in cancer immunotherapy including immune checkpoint inhibitor and adoptive cell transfer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.